(Q33490314)

English

Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma

scientific article published on 4 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Marina Pajic

4

0 references

Andrei V. Gudkov

object named as

Andrei V Gudkov

16

0 references

author name string

Catherine A Burkhart

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Fujiko Watt

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Jayne Murray

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Anatoly Prokvolit

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Chengyuan Xue

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Claudia Flemming

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Janice Smith

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Andrei Purmal

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Nadezhda Isachenko

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Pavel G Komarov

11

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Katerina V Gurova

12

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Alan C Sartorelli

13

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Glenn M Marshall

14

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Murray D Norris

15

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Michelle Haber

17

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

4 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

6573-6580

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Role of the MRP1/ABCC1 multidrug transporter protein in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Targeting multidrug resistance in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

A family of drug transporters: the multidrug resistance-associated proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Structural, mechanistic and clinical aspects of MRP1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

MRP3, an organic anion transporter able to transport anti-cancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Targeted expression of MYCN causes neuroblastoma in transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

21 June 2018

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746061

31 October 2018

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

1 reference

https://pubmed.ncbi.nlm.nih.gov/19654298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19654298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19654298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk

1 reference

https://pubmed.ncbi.nlm.nih.gov/19654298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of mouse skin and the C3HBA mammary carcinoma of the C3H mouse to X-rays and cyclotron neutrons: Effect of mixed neutron—Photon fractionation schemes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19654298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/0008-5472.CAN-09-1075

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33490314&oldid=1535850028"